Next Article in Journal
Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
Next Article in Special Issue
PLEK2, RRM2, GCSH: A Novel WWOX-Dependent Biomarker Triad of Glioblastoma at the Crossroads of Cytoskeleton Reorganization and Metabolism Alterations
Previous Article in Journal
Interactome Mapping of eIF3A in a Colon Cancer and an Immortalized Embryonic Cell Line Using Proximity-Dependent Biotin Identification
Article

An AI-Powered Blood Test to Detect Cancer Using NanoDSF

1
Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France
2
Faculté des Sciences Médicales et Paramédicales, Plateforme Interactome Timone, PINT, Aix Marseille Univ, 13009 Marseille, France
3
Laboratoire Hubert Curien UMR 5516, UJM-Saint-Etienne, CNRS, University Lyon, 42000 Saint Etienne, France
4
CNRS, LIS, Aix-Marseille Univ, 13009 Marseille, France
5
Oracle Labs, San Diego, CA 92121, USA
6
MMG, INSERM, Aix-Marseille Univ, 13009 Marseille, France
7
Service de génétique Médicale, Hôpital de La Timone, APHM, 13005 Marseille, France
8
Biochemistry and Endocrinology, Hôpital de la Conception, APHM, 13005 Marseille, France
9
MEPHI, IRD, APHM, Aix-Marseille Univ, 13274 Marseille, France
10
CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France
11
Service de Neurologie 2-Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
12
Département de Neuropathologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
13
Service d’Anatomie Pathologique et de Neuropathologie, CHU Timone, APHM, 13005 Marseille, France
14
Service de Neuro Oncologie, Hopital de La Timone, APHM, 13005 Marseille, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Maxim V. Berezovski
Cancers 2021, 13(6), 1294; https://doi.org/10.3390/cancers13061294
Received: 14 February 2021 / Revised: 1 March 2021 / Accepted: 3 March 2021 / Published: 15 March 2021
(This article belongs to the Special Issue Biomarker in Glioblastoma)
Brain cancers, such as gliomas, are very difficult to detect because of their localization and late onset of symptoms. Here, we have developed a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of Differential Scanning Fluorimetry. Using blood samples from glioma patients and healthy controls, we show that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. This promising approach can now be extended to other types of cancers and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.
Glioblastoma is the most frequent and aggressive primary brain tumor. Its diagnosis is based on resection or biopsy that could be especially difficult and dangerous in the case of deep location or patient comorbidities. Monitoring disease evolution and progression also requires repeated biopsies that are often not feasible. Therefore, there is an urgent need to develop biomarkers to diagnose and follow glioblastoma evolution in a minimally invasive way. In the present study, we described a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of differential scanning fluorimetry. Using blood samples from 84 glioma patients and 63 healthy controls, we showed that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. Proposed high throughput workflow can be applied to any type of cancer and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.
View Full-Text
Keywords: glioma; biomarker; nanoDSF; diagnostic; liquid biopsy glioma; biomarker; nanoDSF; diagnostic; liquid biopsy
Show Figures

Graphical abstract

MDPI and ACS Style

Tsvetkov, P.O.; Eyraud, R.; Ayache, S.; Bougaev, A.A.; Malesinski, S.; Benazha, H.; Gorokhova, S.; Buffat, C.; Dehais, C.; Sanson, M.; Bielle, F.; Figarella Branger, D.; Chinot, O.; Tabouret, E.; Devred, F. An AI-Powered Blood Test to Detect Cancer Using NanoDSF. Cancers 2021, 13, 1294. https://doi.org/10.3390/cancers13061294

AMA Style

Tsvetkov PO, Eyraud R, Ayache S, Bougaev AA, Malesinski S, Benazha H, Gorokhova S, Buffat C, Dehais C, Sanson M, Bielle F, Figarella Branger D, Chinot O, Tabouret E, Devred F. An AI-Powered Blood Test to Detect Cancer Using NanoDSF. Cancers. 2021; 13(6):1294. https://doi.org/10.3390/cancers13061294

Chicago/Turabian Style

Tsvetkov, Philipp O., Rémi Eyraud, Stéphane Ayache, Anton A. Bougaev, Soazig Malesinski, Hamed Benazha, Svetlana Gorokhova, Christophe Buffat, Caroline Dehais, Marc Sanson, Franck Bielle, Dominique Figarella Branger, Olivier Chinot, Emeline Tabouret, and François Devred. 2021. "An AI-Powered Blood Test to Detect Cancer Using NanoDSF" Cancers 13, no. 6: 1294. https://doi.org/10.3390/cancers13061294

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop